Human LAG-3 Monoclonal Antibody

Catalog No.: YR0133



Basic Information

Molecular Weight 150 kDa

Endotoxin <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility 0.2 µm filtration

Aggregation <5% Determined by SECP

Purity >95% Determined by SDS-PAGE

Background

Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells to attack cancer.Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical P K and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone Relatlimab Biosimilar **Isotype** human IgG4 kappa

Immunogen Human LAG-3

RecommendedIsotype Control(s) In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 6.0

Contact

6	400-999-6126
\times	cn.market@abclonal.com.cn
€	www.abclonal.com.cn

Product Information

Production Purified from cell culture supernatant in an animal-free facility **Purification** Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)